Menu

Randy Schekman to Leave eLife

The founding editor-in-chief will redirect his focus to a Parkinson’s organization.

Aug 19, 2018
Kerry Grens

ABOVE: FLICKR, 2014 ELIFE SCIENCES PUBLICATIONS LTD

Come next year, Randy Schekman will no longer be at the helm of eLife, the journal he launched six years ago, according to a statement. The Nobel laureate will instead devote his efforts to Aligning Science Across Parkinson’s, an organization that is developing research strategies for diagnostics, biomarkers, and therapies.

Schekman, a cell and molecular biologist at the University of California, Berkeley, has been a vocal critic of traditional science publishing for years, even vowing to boycott the high-profile journals where he had reported his Nobel-winning work on vesicle trafficking. Before starting eLife, he served as the editor-in-chief of PNAS. When the opportunity came in 2012 to start fresh with a new publication, Schekman decided to change the way the process was done—making peer reviewers collaborate, using working scientists as editors, shortening the time to publication, and presenting all papers open access. At the beginning, eLife was able to entice submissions by waiving the fees.

eLife has now become a popular online journal. In 2016, for instance, it published for the first time more than 1,000 papers in a year.

Most recently, Schekman and his colleagues at eLife introduced a trial of a new peer-review format in which the journal commits to publishing a paper once the editor has decided to send it out for peer review. Then, both the reviewers’ report and the authors’ response and revised article are published.

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
Have you played Pokemon Go? Then you've used Augmented Reality (AR) technology! AR technology holds substantial promise and potential for providing a low-cost, easy to use digital platform for the manipulation of virtual 3D objects, including 3D models of biological macromolecules.